HTG Molecular Diagnostics, Inc. notified Byron T. Lawson, Senior Vice President and Chief Commercial Officer of the Company, of his termination of employment, effective June 2, 2023. In connection with his termination of employment, the Company has entered into a consulting agreement with Mr. Lawson pursuant to which Mr. Lawson has agreed to provide transition services to the Company for a period anticipated to be one month, in exchange for approximately $23,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | +66.67% | 0.00% | +92.31% |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+92.31% | 5.54K | |
-12.91% | 19.08B | |
-46.21% | 2.65B | |
+18.15% | 1.87B | |
-3.12% | 1.61B | |
+23.78% | 1.21B | |
-10.69% | 1.02B | |
-20.89% | 905M | |
-7.14% | 716M | |
-18.10% | 682M |
- Stock Market
- Equities
- HTGMQ Stock
- News HTG Molecular Diagnostics, Inc.
- Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer